Hope S Rugo is an oncology at the University of California, San Francisco.She specializes in physician and breast oncology.She is a member of Breast Oncology Clinical Trials Program and Department of Medicine .
Hope Rugo, M.D. is a medical oncologist specializing in breast cancer research and treatment.Additionally, she completed a two-year post-doctoral fellowship in immunology at Stanford University.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
To update Wikipedia with this information, visit the page for the subject above.
the University of California, San Francisco
The FDA has cleared technology designed specifically to protect the hair follicles of female breast cancer patients as they undergo chemotherapy. A common side effect of chemotherapy treatments for breast cancer is temporary hair loss. The clearance is the first from the U.S. regulatory agency for a cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy. "Some of today's most powerful, life-saving chemotherapy treatments still cause complete hair loss, a side effect that many women consider to be emotionally devastating," said Dr. Hope Rugo, Principal Investigator for the study and Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center.
The study, presented at the American Society of Clinical Oncology meeting in Chicago, found 69.6 percent of women with advanced breast cancer that were given Mylan’s drug responded to treatment, compared with 64 percent on Herceptin. The results, including early findings that the rates of progression in both groups were identical after six months, are encouraging, said lead researcher Hope Rugo, director of breast oncology clinical trials program at the University of California in San Francisco. Herceptin has improved the chance of survival in those cancers, and a copycat version, known as a biosimilar, will cut the cost, Rugo said. Mylan has already introduced a biosimilar version of Herceptin in India, where more than 5,000 patients have received it, she said.
Two studies published Tuesday in JAMA —, and one from Baylor College of Medicine in Houston — confirmed that women with early-stage breast cancer who underwent scalp-cooling treatments were significantly more likely to keep at least some of their hair throughout chemotherapy. “We have this huge growing population of breast cancer survivors, and many of them are very traumatized by their treatment,” said Dr. Hope S. Rugo, the director of breast oncology and clinical trials education at the U.C.S.F. The women who did not receive scalp-cooling treatment lost most or all of their hair. Scalp cooling is used only in patients with solid tumors, including breast cancer, and may not be appropriate for patients with blood cancers.